Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors

被引：7

作者：

Marcotte, PA ^{[1
]}

Elmore, IN ^{[1
]}

Guan, ZW ^{[1
]}

Magoc, TJ ^{[1
]}

Albert, DH ^{[1
]}

Morgan, DW ^{[1
]}

Curtin, ML ^{[1
]}

Garland, RB ^{[1
]}

Guo, Y ^{[1
]}

Heyman, HR ^{[1
]}

Holms, JH ^{[1
]}

Sheppard, GS ^{[1
]}

Steinman, DH ^{[1
]}

Wada, CK ^{[1
]}

Davidsen, SK ^{[1
]}

机构：

[1] Abbott Labs, Div Pharmaceut Discovery, Canc Res, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF ENZYME INHIBITION | 1999年 / 14卷 / 06期

关键词：

matrix metalloproteinases; MMPs; hydroxamic acid inhibitors;

D O I：

10.3109/14756369909030333

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Two series of compounds synthesized as specific matrix metalloproteinase (MMP) inhibitors have been evaluated for their inhibition of non-MMPs. In a series of substituted succinyl hydroxamic acids, some were found to be significant (IC50 < 1 mu M) inhibitors of leucine (microsomal) aminopeptidase. neprilysin (3.4.24.11), and thermolysin. Macrocyclic compounds in which the alpha carbon of the succinyl hydroxamate is linked to the side chain of the P2' amino acid were found to be good inhibitors of aminopeptidase, but not of neprilysin or thermolysin. Compounds of neither series were found to be significant inhibitors of angiotensin converting enzyme or carboxypeptidase A.

引用

页码：425 / 435

页数：11

共 39 条

[1] Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor [J].

An, ZL ;

Wang, XE ;

Willmott, N ;

Chander, SK ;

Tickle, S ;

Docherty, AJP ;

Mountain, A ;

Millican, AT ;

Morphy, R ;

Porter, JR ;

Epemolu, RO ;

Kubota, T ;

Moossa, AR ;

Hoffman, RM .

CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (02) :184-195

[2] Matrix metalloproteinase inhibitors in arthritis [J].

Bottomley, KM ;

Johnson, WH ;

Walter, DS .

JOURNAL OF ENZYME INHIBITION, 1998, 13 (02) :79-101

[3] BINDING OF BY-PRODUCT ANALOG BENZYLSUCCINIC ACID BY CARBOXYPEPTIDASE A [J].

BYERS, LD ;

WOLFENDEN, R .

BIOCHEMISTRY, 1973, 12 (11) :2070-2078

[4] Orally active inhibitors of stromelysin-1 (MMP-3) [J].

Chapman, KT ;

Durette, PL ;

Caldwell, CG ;

Sperow, KM ;

Niedzwiecki, LM ;

Harrison, RK ;

Saphos, C ;

Christen, AJ ;

Olszewski, JM ;

Moore, VL ;

MacCoss, M ;

Hagmann, WK .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (07) :803-806

[5] Macrocyclic amino carboxylates as selective MMP-8 inhibitors [J].

Cherney, RJ ;

Wang, L ;

Meyer, DT ;

Xue, CB ;

Wasserman, ZR ;

Hardman, KD ;

Welch, PK ;

Covington, MB ;

Copeland, RA ;

Arner, EC ;

DeGrado, WF ;

Decicco, CP .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (11) :1749-1751

[6]

Cockett MI, 1998, BIOCHEM SOC SYMP, P295

[7] Broad spectrum matrix metalloproteinase inhibitors:: An examination of succinamide hydroxamate inhibitors with P1Cα gem-disubstitution [J].

Curtin, ML ;

Garland, RB ;

Davidsen, SK ;

Marcotte, PA ;

Albert, DH ;

Magoc, TJ ;

Hutchins, C .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (12) :1443-1448

[8] DEVELOPMENT AND DESIGN OF SPECIFIC INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME [J].

CUSHMAN, DW ;

CHEUNG, HS ;

SABO, EF ;

ONDETTI, MA .

AMERICAN JOURNAL OF CARDIOLOGY, 1982, 49 (06) :1390-1394

[9] DETERMINANTS ESSENTIAL FOR THE TRANSMISSIBLE GASTROENTERITIS VIRUS-RECEPTOR INTERACTION RESIDE WITHIN A DOMAIN OF AMINOPEPTIDASE-N THAT IS DISTINCT FROM THE ENZYMATIC SITE [J].

DELMAS, B ;

GELFI, J ;

KUT, E ;

SJOSTROM, H ;

NOREN, O ;

LAUDE, H .

JOURNAL OF VIROLOGY, 1994, 68 (08) :5216-5224

[10]

DeLombaert S, 1996, CURR PHARM DESIGN, V2, P443

← 1 2 3 4 →